9
Glandular Lesions of the Uterine Cervix
114. McCluggage WG, Maxwell P. bcl-2 and
p21 immunostaining of cervical tubo-
endometrial metaplasia.
Histopathology
2002;40:107-108.
115. McCluggage WG. Endocervical glan-
dular lesions: controversial aspects
and ancillary techniques.
J Clin Pathol
2003;56:164-173.
116. Baker AC, Eltoum I, Curry RO, et al.
Mucinous expression in benign and
neoplastic glandular lesions of the
uterine cervix.
Arch Pathol Lab Med
2006;130:1510-1515.
117. Li C, Rock KL, Woda BA, et al. IMP3 is a
novel biomarker for adenocarcinoma in
situ of the uterine cervix: an immu-
nohistochemical study in comparison
with p16 INK4A
expression.
Mod Pathol
2007;20:242-247.
118. Wright TC Jr, Massad LS, Dunton CJ,
et al. 2006 census guidelines for the
management of women with abnormal
cervical cancer screening tests.
Am J Ob
Gynecol
2007;197:346-355.
119. Irvin W, Evans SR, Andersen W, et al.
The utility of HPV DNA triage in the
management of cytological AGC.
Am J
Obstet Gynecol
2005;193:559-567.
120. Derchain SFM, Rabelo-Santos SH,
Sarian LO, et al. Human papilloma-
virus DNA detection and histological
findings in women referred for atypical
glandular cells or adenocarcinoma in
situ in their Pap smear.
Gynecol Oncol
2004;95:618-623.
121. Stoler MH. Testing for human papil-
lomavirus: data driven implications for
cervical neoplasia management.
Clin
Lab Med
2003;23:569-583.
245
previous page 246 ComprehensiveCytopathology 1104p 2008 read online next page 248 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off